Deutsche Bank on Legend Biotech Corp. (LEGN): 'Most incremental, in our view, LEGN will share first patient data for its in-vivo CAR T program by YE26'
Tweet Send to a Friend
Deutsche Bank analyst James Shin reiterated a Buy rating and $60.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
